Welcome to BioSeeker Group!

Triple Analysis: Lymphoma, Angiogenesis and Antibodies

Additional Information

Published Date Nov 1, 2012
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 5019
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Lymphoma, Angiogenesis and Antibodies in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lymphoma), one mechanism/target/effect area (Angiogenesis) and one compound specific area (Antibodies).

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lymphoma, Angiogenesis and Antibodies.

    To find out more about Triple Analysis: Lymphoma, Angiogenesis and Antibodies, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lymphoma, Angiogenesis and Antibodies is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lymphoma), one mechanism/target/effect area (Angiogenesis) and one compound specific area (Antibodies). Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Lymphoma
The lymphoma report part comprises defined and up to date development strategies for 282 lymphoma drugs within the portfolio of 154 investigators, from Ceased to Marketed. This part extensively analyses their 181 identified drug targets, organized into 173 drug target strategies, and assesses them in eight different compound strategies and and five subindications of lymphoma.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market

Part II: Angiogenesis
The angiogenesis affecting cancer drug report part comprises defined and up to date development strategies for 252 drugs in oncology within the portfolio of 151 companies world-wide, from Ceased to Marketed. The report extensively analyses their 177 identified drug targets, organized into 170 drug target strategies, and assesses them in 70 cancer indications.
This part is based on the following publication:
Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

Part III: Antibodies
The antibody drug report part comprises defined and up to date development strategies for 572 drugs in oncology within the portfolio of 205 companies world-wide, from Ceased to Marketed. The report extensively analyses their 270 identified drug targets, organized into 279 drug target strategies, and assesses them in 72 cancer indications.
This part is based on the following publication:
Cancer Antibodies: Drug Target Atlas and Competitive Outlook

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Lymphoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Lymphoma Drugs for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 30-387
7 Emerging New Products to Established Ones: Drug Target Strategies of Lymphoma Drugs by their Highest Stage of Development (173 Drug Target Strategies and 282 Lymphoma Drugs) 388-596
8 Compound Strategies at Work: Competitive Benchmarking of Lymphoma Drugs by Compound Strategy (8 Compound Strategies) 597-636
9 Selecting Subindication for Lymphoma Drugs (Five Subindications of Lymphoma) 637-657
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lymphoma Drug Pipeline by Investigator (152 Companies) 658-938
11 Disclaimer 939
12 Drug Index 940
13 Company Index 948
Figures: Includes 6 Figures
Tables: Includes 222 Tables
Total Number of Pages: 954

Part II: Angiogenesis
5.1 The Scope of this Report 37
6 Consider the Therapeutic Target Among Angiogenesis Affecting Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (177 Drug Targets) 41-421
7 Emerging New Products to Established Ones: Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology by their Highest Stage of Development (170 Drug Target Strategies and 252 Drugs) 424-666
8 Compound Strategies at Work: Competitive Benchmarking of Angiogenesis Affecting Cancer Drugs by Compound Strategy (7 Compound Strategies) 667-709
9 Selecting Indication for Angiogenesis Affecting Drugs in Oncology (70 Cancer Indications) 710-848
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (151 Investigators and 252 Drugs) 849-1685
12 Drug Index 1687
13 Company Index 1697
Figures: Includes 7 Figures
Tables: Includes 310 Tables
Total Number of Pages: 1,704

Part III: Antibodies
5.1 The Scope of this Report 35
6 Consider the Therapeutic Target Among Antibody Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (270 Drug Targets) 39
7 Emerging Drug Candidates to Established Ones: Drug Target Strategies of Antibody Drugs in Cancer by their Highest Stage of Development (279 Drug Target Strategies and 572 Drugs) 423-776
8 Selecting Indication for Antibody Drugs in Oncology (72 Cancer Indications) 777-907
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Antibody Drug Pipeline by Investigator (205 Investigators and 572 Drugs) 908-2360
10 Disclaimer 2361
Figures: Includes 7 Figures
Tables: Includes 355 Tables
Total Number of Pages: 2,361

This Report Includes the Following Companies:
4SC
A&G Pharmaceutical
Abbott
Abcam
Abiogen
Ablynx
AC Immune
Acceleron Pharma
Access
Actinium Pharmaceuticals
Active Biotech
Adherex
Advantagene
Advaxis
Advenchen
AEgera
AEterna Zentaris
Affibody
Affimed Therapeutics
Affitech
Agennix
Agenus
AGY Therapeutics
Aida Pharmaceuticals
Alder Biopharmaceuticals
Alethia Biotherapeutics
Alexion
Alfa Wassermann
Alfacell
Algeta
Allos Therapeutics
Alnylam
ALSP
Altor BioScience
Ambit Biosciences
Ambrilia Biopharma
Amgen
Amorfix Life Sciences
Amphora
Angiogen
Angiogenex
Angstrom Pharmaceuticals
Ansaris
Antisoma
Aphios
Apricus Biosciences
Arana Therapeutics
Arca biopharma
Areva
arGEN-X
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Ascenta Therapeutics
Astellas
Astex Therapeutics
AstraZeneca
Attenuon
Austrianova
AVEO
Bayer
Benitec
Berkeley Lab
BioAlliance Pharma
BioAxone
Biocad
Biocon
BioCryst Pharmaceuticals
Biogen Idec
BioInvent
Biolex
BioLineRx
Biosceptre
Biotecnol
Biotest
Boehringer Ingelheim
Bolder BioTechnology
Borean Pharma
Bristol-Myers Squibb
BTG
Cancer Innovations
Cancer Research Technology
CDG Therapeutics
Celecure
Celera
Celgene
Cell Therapeutics
CellCeutix
Celldex Therapeutics
Cellmid
Celltrion
Celtic Pharma
Center of Molecular Immunology
Centrose
Cephalon
CG Therapeutics
ChemoCentryx
Chemokine Therapeutics
China Sky One Medical
Choongwae
Circadian Technologies
Cornerstone Pharmaceuticals
CSL
Cue Biotech
CuraGen
CureTech
Curis
Customized Therapeutics
Cyclacel
Cylene Pharmaceuticals
CytImmune Sciences
Cytochroma
Cytokinetics
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Deciphera Pharmaceuticals
Dendreon
DiaMedica
Dompe
Dr Reddy’s
Dyax
Dynavax Technologies
Eisai
Elan
Eleos
Eli Lilly
Emergent BioSolutions
EntreMed
Enzon
EpiCept
Epizyme
Ergon Pharmaceuticals
EUSA Pharma
Exelixis
ExonHit Therapeutics
Expression Drug Designs
Fabrus
Faron Pharmaceuticals
Favrille
Femta Pharmaceuticals
FibroGen
Five Prime Therapeutics
Forma Therapeutics
Fusion Antibodies
Galaxy Biotech
GammaCan
Ganymed Pharmaceuticals
Gemin X Biotechnologies
Gene Techno Science
Genencor
Genentech
Genmab
Genomic Systems
GenPat77
Genta
Genzyme
Gilead Sciences
GlaxoSmithKline
Gliknik
GlycoGenesys
Glycotope
Green Cross
Hawthorn Pharmaceuticals
Hayashibara
Heber Biotec
HemaQuest
Hoffmann-La Roche
Human Genome Sciences
Hy BioPharma
Idera Pharmaceuticals
IDM Pharma
IGF Oncology
ImClone Systems
IMED
Immune Pharmaceuticals
ImmunoCellular Therapeutics
ImmunoGen
Immunomedics
ImmuPharma
Immutep
Inex
Innate Pharma
InNexus Biotechnology
Inovio
Intas Biopharmaceuticals
Intracel
Introgen Therapeutics
ISA Pharmaceuticals
Isis Pharmaceuticals
ISU ABXIS
Italfarmaco
Johnson & Johnson
KAI Pharmaceuticals
Kaketsuken
KaloBios
Karus Therapeutics
Kinex
Kirin Pharma
Kissei
Kringle Pharma
Kyowa Hakko Kirin
Kyto Biopharma
Lee’s Pharmaceutical
Leo
LFB Biotechnologies
LG Life Sciences
Ligand
Lorus Therapeutics
MacroGenics
MAT Biopharma
Meda
Medarex
MediGene
MedImmune
Menarini
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
Mitsubishi Tanabe Pharma
MolMed
Morvus Technology
Mycenax
Nektar Therapeutics
Neovacs
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neuren
NewSouth Innovations
NIH
NKT Therapeutics
Non-industrial source
Northwest Biotherapeutics
Novartis
Novelix
Noxxon
Nycomed Pharma
Oasmia
OncoMed
Onconova
OncoTherapy Science
Oncothyreon
Onyvax
OSI Pharmaceuticals
Otsuka
Oxford BioMedica
OXiGENE
Paladin Labs
Panacea
PanGenetics
Patrys
Pepscan Therapeutics
PepTx
Peregrine Pharmaceuticals
Perseus Proteomics
Pfizer
PharmAbcine
Pharmacopeia
Pharmacyclics
PharmaMar
Pharminox
Philogen
PhiloGene
Pierre Fabre
Piramal
Plexxikon
Portola Pharmaceuticals
Prima Biomed
PROBIOMED
ProCell Therapeutics
Prochon Biotech
Progen
Progenics Pharmaceuticals
ProNAi Therapeutics
Protein Sciences
Protgen
PTC Therapeutics
Ramot
Reata Pharmaceuticals
Recepta biopharma
Receptor BioLogix
Regeneron
Reliance Life Sciences
Rexahn
Rigel
Sanofi
Sanofi-Aventis
Santaris Pharma
SBI Biotech
SBIO
Scancell
SciClone Pharmaceuticals
Seattle Genetics
Selvita
Semafore Pharmaceuticals
Shanghai CP Guojian
Shenogen
Shionogi
Shire
Simcere Pharmaceuticals
Spear Therapeutics
SRI International
Stainwei Biotech
Sunol Molecular
SuperGen
SuppreMol
Switch Pharma
Symphogen
Synageva BioPharma
SynDevRx
SynerGene Therapeutics
Tactic Pharma
Taiho
Takeda
Tamir Biotechnology
Tapestry Pharmaceuticals
Targa Therapeutics
Tau Therapeutics
TeGenero
Tekmira Pharmaceuticals
Telik
TetraLogic Pharmaceuticals
Teva
ThromboGenics
Tigris Pharmaceuticals
Titan Pharmaceuticals
Tolerx
ToolGen
TopoTarget
Tracon Pharmaceuticals
Transgene
Trillium Therapeutics
Trion Pharma
UCB
United Therapeutics
Vaccinex
Wakunaga
VasGene Therapeutics
VBL Therapeutics
VentiRx Pharmaceuticals
Vertex Pharmaceuticals
Wilex
Vion Pharmaceuticals
Viragen
Viventia Biotech
XBiotech
Xencor
Xerion
Xoma
Y’s Therapeutics
Yakult Honsha
YM BioSciences
Zenotech
Zenyaku Kogyo
A Shortlist of Drugs Included are:
131I-tositumomab
A6
abagovomab
ABT-510
adecatumumab
aflibercept
AGS-1C4D4
ALD-518
alemtuzumab
amatuximab
AME-133
AMG-386
amrubicin hydrochloride
Angiozyme
apatinib
ARQ-197
atrasentan
AV-299
axitinib
belimumab
belinostat
bevacizumab
bexarotene
BHQ880
BIBF-1120
blinatumomab
BMS-663513
BMS-690514
BMS-936558
bortezomib
brentuximab vedotin
brivanib alaninate
BT-062
carlumab
catumaxomab
CDX-1307
CDX-1401
cediranib
cetuximab
cilengitide
cixutumumab
cladribine
CMAB302
CMAB304
conatumumab
CT-011
dalotuzumab
daratumumab
denileukin diftitox
denosumab
DI-17E6
dovitinib lactate
E-7820
elliptinium acetate
elotuzumab
EMD-273063
EMD525797
endostatin
ENMD-2076
enzastaurin hydrochloride
epirubicin
epratuzumab
epratuzumab-Y90
ertumaxomab
everolimus
Exherin
farletuzumab
figitumumab
foretinib
fosbretabulin tromethamine
fresolimumab
galiximab
ganitumab
gemtuzumab ozogamicin
girentuximab
glembatumumab vedotin
GliaAtak
GS-6634
GT-111
HBP-347
I-131-labetuzumab
ibritumomab tiuxetan
icrucumab
inotuzumab ozogamicin
interferon (alpha)
interferon (alpha2b)
interferon (gamma)
interferon alfa-2b
interferon alpha-2b
intetumumab
IPH-2102
ipilimumab
IPP-204106
iratumumab
irinotecan hydrochloride
JI-101
L19-TNFalpha
lenvatinib
linifanib
lintuzumab
LIP-131I
lorvotuzumab mertansine
lucatumumab
lumiliximab
LY-2275796
LY2495655
lymphomun
MABp1
mapatumumab
MCS-110
MEDI-551
MEDI-573
MGCD-265
midostaurin
milatuzumab
milatuzumab-doxorubicin
mitoxantrone
MM-111
MM-121
mogamulizumab
MOR202
MOR208
MORAb-004
motesanib diphosphate
moxetumomab pasudotox
muparfostat (IV)
naptumomab estafenatox
natalizumab
necitumumab
NGR-TNF
nimotuzumab
obinutuzumab
oblimersen sodium
ofatumumab
olaratumab
ON-01910
onartuzumab
Onyvax-105
oregovomab
OTS-102
paclitaxel
PancAtak
panitumumab
panobinostat
PAT-SC1
pazopanib hydrochloride
PCI-27483
pegdinetanib
pertuzumab
PF-4856884
pixantrone
plitidepsin
ponatinib
pralatrexate
ProstAtak
PTC-299
RAF-265
ramucirumab
razoxane
Reditux
regorafenib
RG-7160
rhIFN-alpha
ridaforolimus
rilotumumab
rituximab
robatumumab
romidepsin
romiplostim
samalizumab
SAR-3419
siltuximab
sirolimus
sobuzoxane
sorafenib tosylate
sotatercept
SU-6668
sunitinib malate
Sym-004
talactoferrin alfa
TAS-102
tasquinimod
TB-403
telatinib
temsirolimus
Tenarad
teniposide
thymalfasin
tigatuzumab
tipifarnib
tivozanib
tocilizumab
TRC-105
tremelimumab
TRU-016
tucotuzumab celmoleukin
U3-1287
Ublituximab
vandetanib
veltuzumab
vismodegib
volociximab
XL-184
XL-647
yttrium Y 90 clivatuzumab tetraxetan
zalutumumab
zanolimumab

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lymphoma, Angiogenesis and Antibodies.
    To find out more about Triple Analysis: Lymphoma, Angiogenesis and Antibodies, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lymphoma, Angiogenesis and Antibodies is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Colorectal Cancer, Lung Cancer and Peptides
This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Lung Cancer and by the compound strategy of Peptides. Learn More


Triple Analysis: Leukemia, Melanoma and Prostate Cancer
This triple analysis focuses on cancer drug development strategies in Leukemia, Melanoma and Prostate Cancer. Learn More

Other selected research from the 'Oncology' category:


Ovarian Cancer Drug Pathway Analyzer
There are today at least 439 targeted molecular therapies known to affect more than 250 specific intracellular signaling pathways for the treatment of ovarian cancer. The rational for this plethora of treatment strategies is based on our increasing understanding of the 291 drug targets that are included in this drug-pathway analyzing tool. No less than 275 of these have been recorded with mutations and 51 drug targets have mutations which have been causally implicated in cancer. Learn More


Triple Analysis: Lymphoma, Pancreatic Cancer and Angiogenesis
This triple analysis focuses on cancer drug development strategies in both Lymphoma and Pancreatic Cancer and by the mechanism/target/effect of Angiogenesis. Learn More